We are live on ! Find out more
IC

Ikarian Capital Portfolio holdings

AUM $1.23B
1-Year Est. Return 600.17%
This Fund
S&P 500
This Quarter Est. Return
+69.49%
1 Year Est. Return
+600.17%
3 Year Est. Return
+5,763.15%
5 Year Est. Return
+15,527.6%
10 Year Est. Return
–
AUM
$617M
AUM Growth
–
Cap. Flow
+$516M
Cap. Flow %
83.64%
Top 10 Hldgs %
46.54%
Holding
114
New
114
Increased
–
Reduced
–
Closed
–

Top Buys

Rank Stock Value
1
SAGE
Sage Therapeutics
SAGE
+$16.4M
2
CHMA
Chiasma, Inc. Common Stock
CHMA
+$5.74M
3
IMVT icon
Immunovant
IMVT
+$5.65M
4
AUPH icon
Aurinia Pharmaceuticals
AUPH
+$4.43M
5
MDGL icon
Madrigal Pharmaceuticals
MDGL
+$4.34M

Top Sells

No sells this quarter

Sector Composition

Rank Sector Weight
1 Healthcare 16.17%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
VKTX icon
76
PUT
Viking Therapeutics
VKTX
$3.82B
$1.2M 0.19%
+150,000
New +$1.09M
PBYI icon
77
CALL
Puma Biotechnology
PBYI
$397M
$1.16M 0.19%
+132,700
New +$1.1M
DTIL icon
78
Precision BioSciences
DTIL
$175M
$1.11M 0.18%
+2,667
New +$838K
WVE icon
79
CALL
Wave Life Sciences
WVE
$1.09B
$1.08M 0.17%
+134,400
New +$3.29M
VKTX icon
80
Viking Therapeutics
VKTX
$3.82B
$1.01M 0.16%
+126,159
New +$920K
SIOX
81
DELISTED
Sio Gene Therapies Inc. Common Stock
SIOX
$967K 0.16%
+188,884
New +$1.05M
AGTC
82
DELISTED
Applied Genetic Technologies Corporation
AGTC
$908K 0.15%
+200,884
New +$635K
DBVT
83
DBV Technologies
DBVT
$795M
$798K 0.13%
+7,454
New +$596K
NBIX icon
84
CALL
Neurocrine Biosciences
NBIX
$18.2B
$774K 0.13%
+7,200
New +$754K
RIGL icon
85
Rigel Pharmaceuticals
RIGL
$713M
$749K 0.12%
+35,000
New +$721K
NERV icon
86
Minerva Neurosciences
NERV
$195M
$711K 0.12%
+12,500
New +$551K
PGNX
87
DELISTED
Progenics Pharmaceuticals Inc
PGNX
$666K 0.11%
+130,845
New +$692K
BLU
88
DELISTED
BELLUS Health Inc.
BLU
$625K 0.1%
+63,721
New +$436K
OCUL icon
89
CALL
Ocular Therapeutix
OCUL
$1.83B
$593K 0.1%
+150,000
New +$522K
MTEM
90
DELISTED
Molecular Templates, Inc.
MTEM
$572K 0.09%
+2,727
New +$392K
PTGX icon
91
Protagonist Therapeutics
PTGX
$8.68B
$552K 0.09%
+78,326
New +$778K
NERV icon
92
CALL
Minerva Neurosciences
NERV
$195M
$530K 0.09%
+9,313
New +$411K
PRTA icon
93
Prothena Corp
PRTA
$442M
$472K 0.08%
+29,832
New +$320K
CMRX
94
DELISTED
Chimerix, Inc.
CMRX
$351K 0.06%
+172,920
New +$319K
DRNA
95
CALL
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
$341K 0.06%
+15,500
New +$312K
OBSV
96
DELISTED
ObsEva SA Ordinary Shares
OBSV
$315K 0.05%
+82,573
New +$429K
TVRD
97
CALL
Tvardi Therapeutics
TVRD
$22.1M
$285K 0.05%
+492
New +$345K
ZGNX
98
CALL
DELISTED
Zogenix, Inc.
ZGNX
$240K 0.04%
+4,600
New +$211K
TARA icon
99
Protara Therapeutics
TARA
$214M
$138K 0.02%
+8,409
New +$96.5K
SRRA
100
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
$132K 0.02%
+9,660
New +$126K
1 2 3
4
5

Similar funds

FLII
First Long Island Investors Jericho, New York $1.23B AUM 14.42% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
HCA
Harbor Capital Advisors Chicago, Illinois $1.23B AUM 30.56% 1-Year Est. Return
GX
Greylock XIV Menlo Park, California $1.24B AUM
WCM
Windward Capital Management Los Angeles, California $1.23B AUM 23.17% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
IA
Inspire Advisors Meridian, Idaho $1.23B AUM 18.62% 1-Year Est. Return
IB
Intrust Bank Wichita, Kansas $1.23B AUM 26.34% 1-Year Est. Return

Ikarian Capital's Q4 2019 Portfolio in Review

Q4 2019 is the first quarter with a 13F filing on record for Ikarian Capital, which disclosed 114 positions worth $617M. Its ten largest holdings account for 47% of the portfolio.

Its largest position is Sage Therapeutics: 133,000 shares worth $9.6M.

By sector, the portfolio is most concentrated in Healthcare at 16% of assets.

  • Ikarian Capital's largest Q4 2019 buy was Sage Therapeutics: 133,000 shares worth $9.6M.
  • Ikarian Capital's ten largest holdings make up 47% of its $617M portfolio in Q4 2019.
  • Ikarian Capital disclosed 114 positions in Q4 2019, its first 13F filing on record.

Based on Ikarian Capital's 13F filing for Q4 2019, filed 31 Jan 2020.